Opdivo Approval and Use in Melanoma
The FDA approved Opdivo (nivolumab) in 2014 for unresectable or metastatic melanoma, based on phase 3 CheckMate-037 trial data showing it outperformed chemotherapy in patients who failed prior ipilimumab therapy.[1] It's now a first-line option, often combined with Yervoy (ipilimumab), for advanced melanoma with BRAF mutations or wild-type.[2]
Key Clinical Trial Results
In CheckMate-066, Opdivo monotherapy yielded a 40% objective response rate (ORR) and median overall survival (OS) of 37.6 months versus 19 months for dacarbazine.[1][3] The CheckMate-067 trial tested Opdivo + Yervoy: 58% ORR, 5-year OS of 52%, and 7-year OS of 49%—doubling survival rates compared to Yervoy alone (26% ORR, 7-year OS 34%).[4][5] For adjuvant use post-surgery (CheckMate-238), it cut recurrence risk by 35% versus ipilimumab (3-year recurrence-free survival 58% vs 52%).[6]
| Trial | Setting | ORR | Median OS | 5-Year OS |
|-------|---------|-----|-----------|-----------|
| CheckMate-067 (Opdivo + Yervoy) | First-line metastatic | 58% | Not reached | 52% |
| CheckMate-067 (Opdivo alone) | First-line metastatic | 44% | 36 months | 44% |
| CheckMate-238 (adjuvant) | High-risk resected | N/A | N/A | 68% (RFS at 3 years) |
Responses often last years; about 20-30% achieve complete responses.[4]
How It Compares to Other Treatments
Opdivo + Yervoy beats PD-1 monotherapy or ipilimumab alone in OS and durable responses, per CheckMate-067.[4] Versus targeted BRAF/MEK inhibitors (e.g., Tafinlar + Mekinist), the combo shows similar ORR (67% vs 64%) but better long-term OS in BRAF-wildtype patients.[7] Keytruda (pembrolizumab) has comparable 5-year OS (34-39% monotherapy), but head-to-head data favor no clear winner.[8]
Who Responds Best and Limitations
PD-L1 expression predicts better outcomes (ORR 55% if PD-L1 ≥5% vs 41% if <5%).[3] Effectiveness drops in BRAF-mutated cases without combo therapy. Real-world data confirm trial results, with 3-year OS around 50%.[9] Not curative for all; 40-50% progress within 2 years.
Common Side Effects Patients Report
Immune-related adverse events hit 96% on combo therapy: fatigue (60%), rash (50%), colitis (40%), hepatitis (20%). Severe (grade 3/4) in 59%; some require steroids or hospitalization.[4][10] Melanoma patients note skin issues and thyroid problems most frequently in forums and studies.
Ongoing Trials and Future Outlook
Phase 3 trials test Opdivo with relatlimab (Opdualag, approved 2022) for better ORR (48% vs 37%).[11] Neoadjuvant studies show 50-70% major pathologic responses.[12]
Sources
[1]: FDA Label
[2]: NCCN Guidelines
[3]: NEJM 2015 CheckMate-066
[4]: NEJM 2017 CheckMate-067
[5]: Nature Med 2021 7-year update
[6]: NEJM 2017 CheckMate-238
[7]: Lancet Oncol 2019 DREAMseq
[8]: JCO 2020 KEYNOTE-006
[9]: JAMA Oncol 2021 real-world
[10]: CheckMate-067 safety update
[11]: RELATIVITY-047 NEJM 2022
[12]: Nature 2023 neoadjuvant meta-analysis